Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review
Introduction Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patien...
Gespeichert in:
Veröffentlicht in: | Advances in therapy 2023-01, Vol.40 (1), p.117-132 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 132 |
---|---|
container_issue | 1 |
container_start_page | 117 |
container_title | Advances in therapy |
container_volume | 40 |
creator | Lohsiriwat, Varut Sheikh, Parvez Bandolon, Robert Ren, Dong-Lin Roslani, April Camilla Schaible, Kassandra Freitag, Andreas Martin, Monique Yaltirik, Pelin Godeberge, Philippe |
description | Introduction
Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD.
Methods
Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews.
Results
The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most (
n
= 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments.
Conclusion
The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence.
Graphical abstract
Plain Language Summary
Patients with hemorrhoidal disease (HD) can experience recurring disease following a period of improvement or remission. It is not well established how often this might happen, who is at greatest risk, or which treatments can reduce this risk. In this study, a systematic literature review (SLR) was conducted to summarize evidence on the occurrence and recurrence of HD, as well as treatment effectiveness. Several literature databases were searched for articles that described real-world e |
doi_str_mv | 10.1007/s12325-022-02351-7 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9859842</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2732540359</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-5da4adc4c656871b86da2dad9a7900a59f9d017b853086e804038e454cbe27b3</originalsourceid><addsrcrecordid>eNp9kU9v1DAQxS0EokvhC3BAPnIJ-G_scECqWmiRKoGWPXBAsib27K6rJC52UtRvj-mWCi4cRnN4b96M5kfIS87ecMbM28KFFLphQtSSmjfmEVlx2-qmlnhMVswo3ghpvx2RZ6VcMSaY0fYpOZKtlNxotSLf1-iXnHHySNcwY6EwBfplD3kEn4a0ix4GuskI84jTTLcp0wscU877FEOVzmJBKPiOntCvt2XGEebo6RpvIv58Tp5sYSj44r4fk83HD5vTi-by8_mn05PLxivVzo0OoCB45VvdWsN72wYQAUIHpmMMdLftAuOmt1oy26JlikmLSivfozC9PCbvD7HXSz9i8PXODIO7znGEfOsSRPevMsW926Ub11ndWSVqwOv7gJx-LFhmN8bicRhgwrQUJ0z9c12qu2oVB6vPqZSM24c1nLnfVNyBiqtU3B0VZ-rQq78PfBj5g6Ea5MFQqjTtMLurtOSp_ux_sb8AioOZww</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2732540359</pqid></control><display><type>article</type><title>Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Lohsiriwat, Varut ; Sheikh, Parvez ; Bandolon, Robert ; Ren, Dong-Lin ; Roslani, April Camilla ; Schaible, Kassandra ; Freitag, Andreas ; Martin, Monique ; Yaltirik, Pelin ; Godeberge, Philippe</creator><creatorcontrib>Lohsiriwat, Varut ; Sheikh, Parvez ; Bandolon, Robert ; Ren, Dong-Lin ; Roslani, April Camilla ; Schaible, Kassandra ; Freitag, Andreas ; Martin, Monique ; Yaltirik, Pelin ; Godeberge, Philippe</creatorcontrib><description>Introduction
Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD.
Methods
Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews.
Results
The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most (
n
= 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments.
Conclusion
The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence.
Graphical abstract
Plain Language Summary
Patients with hemorrhoidal disease (HD) can experience recurring disease following a period of improvement or remission. It is not well established how often this might happen, who is at greatest risk, or which treatments can reduce this risk. In this study, a systematic literature review (SLR) was conducted to summarize evidence on the occurrence and recurrence of HD, as well as treatment effectiveness. Several literature databases were searched for articles that described real-world evidence (RWE) studies reporting the epidemiology or recurrence of HD as well as published SLRs that combined the results of multiple studies (meta-analyses) on treatment for adults with HD. Forty of 2037 articles identified by the search were considered relevant, and four others identified by clinicians were also included (total = 44; 39 RWE, 5 meta-analyses). Review of the RWE articles revealed that HD epidemiology was determined differently between studies. Only 23 reported recurrence rates (up to 56.5%) after surgery or treatment with phlebotonic drugs (drugs that improve blood flow in veins). Most (19/23) reported recurrence rates of 20% or less. Risk factors for recurrence were similar to usual HD risk factors (e.g., constipation, male gender, age) in addition to time since treatment. Phlebotonic agents, including those made from plant extracts (micronized purified flavonoid fractions, MPFFs) improved hemorrhoidal symptoms compared with placebo or no treatment. In one meta-analysis, MPFF was the only phlebotonic to significantly reduce recurrence risk versus no treatment or placebo. Overall, more research is needed to compare treatments and determine optimal treatment duration to prevent recurrence.
BeGGY4JXaFY15gccdi8jpH
Author-narrated video abstract</description><identifier>ISSN: 0741-238X</identifier><identifier>EISSN: 1865-8652</identifier><identifier>DOI: 10.1007/s12325-022-02351-7</identifier><identifier>PMID: 36331754</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Adult ; Cardiology ; Endocrinology ; Flavonoids ; Hemorrhage ; Hemorrhoids - drug therapy ; Hemorrhoids - epidemiology ; Humans ; Internal Medicine ; Male ; Medicine ; Medicine & Public Health ; Meta-Analysis as Topic ; Oncology ; Pharmacology/Toxicology ; Review ; Rheumatology ; Risk Factors</subject><ispartof>Advances in therapy, 2023-01, Vol.40 (1), p.117-132</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-5da4adc4c656871b86da2dad9a7900a59f9d017b853086e804038e454cbe27b3</citedby><cites>FETCH-LOGICAL-c446t-5da4adc4c656871b86da2dad9a7900a59f9d017b853086e804038e454cbe27b3</cites><orcidid>0000-0001-5599-8654 ; 0000-0002-2252-9509 ; 0000-0003-2153-2930 ; 0000-0003-2458-965X ; 0000-0003-4645-9864</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12325-022-02351-7$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12325-022-02351-7$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36331754$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lohsiriwat, Varut</creatorcontrib><creatorcontrib>Sheikh, Parvez</creatorcontrib><creatorcontrib>Bandolon, Robert</creatorcontrib><creatorcontrib>Ren, Dong-Lin</creatorcontrib><creatorcontrib>Roslani, April Camilla</creatorcontrib><creatorcontrib>Schaible, Kassandra</creatorcontrib><creatorcontrib>Freitag, Andreas</creatorcontrib><creatorcontrib>Martin, Monique</creatorcontrib><creatorcontrib>Yaltirik, Pelin</creatorcontrib><creatorcontrib>Godeberge, Philippe</creatorcontrib><title>Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review</title><title>Advances in therapy</title><addtitle>Adv Ther</addtitle><addtitle>Adv Ther</addtitle><description>Introduction
Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD.
Methods
Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews.
Results
The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most (
n
= 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments.
Conclusion
The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence.
Graphical abstract
Plain Language Summary
Patients with hemorrhoidal disease (HD) can experience recurring disease following a period of improvement or remission. It is not well established how often this might happen, who is at greatest risk, or which treatments can reduce this risk. In this study, a systematic literature review (SLR) was conducted to summarize evidence on the occurrence and recurrence of HD, as well as treatment effectiveness. Several literature databases were searched for articles that described real-world evidence (RWE) studies reporting the epidemiology or recurrence of HD as well as published SLRs that combined the results of multiple studies (meta-analyses) on treatment for adults with HD. Forty of 2037 articles identified by the search were considered relevant, and four others identified by clinicians were also included (total = 44; 39 RWE, 5 meta-analyses). Review of the RWE articles revealed that HD epidemiology was determined differently between studies. Only 23 reported recurrence rates (up to 56.5%) after surgery or treatment with phlebotonic drugs (drugs that improve blood flow in veins). Most (19/23) reported recurrence rates of 20% or less. Risk factors for recurrence were similar to usual HD risk factors (e.g., constipation, male gender, age) in addition to time since treatment. Phlebotonic agents, including those made from plant extracts (micronized purified flavonoid fractions, MPFFs) improved hemorrhoidal symptoms compared with placebo or no treatment. In one meta-analysis, MPFF was the only phlebotonic to significantly reduce recurrence risk versus no treatment or placebo. Overall, more research is needed to compare treatments and determine optimal treatment duration to prevent recurrence.
BeGGY4JXaFY15gccdi8jpH
Author-narrated video abstract</description><subject>Adult</subject><subject>Cardiology</subject><subject>Endocrinology</subject><subject>Flavonoids</subject><subject>Hemorrhage</subject><subject>Hemorrhoids - drug therapy</subject><subject>Hemorrhoids - epidemiology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-Analysis as Topic</subject><subject>Oncology</subject><subject>Pharmacology/Toxicology</subject><subject>Review</subject><subject>Rheumatology</subject><subject>Risk Factors</subject><issn>0741-238X</issn><issn>1865-8652</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU9v1DAQxS0EokvhC3BAPnIJ-G_scECqWmiRKoGWPXBAsib27K6rJC52UtRvj-mWCi4cRnN4b96M5kfIS87ecMbM28KFFLphQtSSmjfmEVlx2-qmlnhMVswo3ghpvx2RZ6VcMSaY0fYpOZKtlNxotSLf1-iXnHHySNcwY6EwBfplD3kEn4a0ix4GuskI84jTTLcp0wscU877FEOVzmJBKPiOntCvt2XGEebo6RpvIv58Tp5sYSj44r4fk83HD5vTi-by8_mn05PLxivVzo0OoCB45VvdWsN72wYQAUIHpmMMdLftAuOmt1oy26JlikmLSivfozC9PCbvD7HXSz9i8PXODIO7znGEfOsSRPevMsW926Ub11ndWSVqwOv7gJx-LFhmN8bicRhgwrQUJ0z9c12qu2oVB6vPqZSM24c1nLnfVNyBiqtU3B0VZ-rQq78PfBj5g6Ea5MFQqjTtMLurtOSp_ux_sb8AioOZww</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Lohsiriwat, Varut</creator><creator>Sheikh, Parvez</creator><creator>Bandolon, Robert</creator><creator>Ren, Dong-Lin</creator><creator>Roslani, April Camilla</creator><creator>Schaible, Kassandra</creator><creator>Freitag, Andreas</creator><creator>Martin, Monique</creator><creator>Yaltirik, Pelin</creator><creator>Godeberge, Philippe</creator><general>Springer Healthcare</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5599-8654</orcidid><orcidid>https://orcid.org/0000-0002-2252-9509</orcidid><orcidid>https://orcid.org/0000-0003-2153-2930</orcidid><orcidid>https://orcid.org/0000-0003-2458-965X</orcidid><orcidid>https://orcid.org/0000-0003-4645-9864</orcidid></search><sort><creationdate>20230101</creationdate><title>Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review</title><author>Lohsiriwat, Varut ; Sheikh, Parvez ; Bandolon, Robert ; Ren, Dong-Lin ; Roslani, April Camilla ; Schaible, Kassandra ; Freitag, Andreas ; Martin, Monique ; Yaltirik, Pelin ; Godeberge, Philippe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-5da4adc4c656871b86da2dad9a7900a59f9d017b853086e804038e454cbe27b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adult</topic><topic>Cardiology</topic><topic>Endocrinology</topic><topic>Flavonoids</topic><topic>Hemorrhage</topic><topic>Hemorrhoids - drug therapy</topic><topic>Hemorrhoids - epidemiology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-Analysis as Topic</topic><topic>Oncology</topic><topic>Pharmacology/Toxicology</topic><topic>Review</topic><topic>Rheumatology</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lohsiriwat, Varut</creatorcontrib><creatorcontrib>Sheikh, Parvez</creatorcontrib><creatorcontrib>Bandolon, Robert</creatorcontrib><creatorcontrib>Ren, Dong-Lin</creatorcontrib><creatorcontrib>Roslani, April Camilla</creatorcontrib><creatorcontrib>Schaible, Kassandra</creatorcontrib><creatorcontrib>Freitag, Andreas</creatorcontrib><creatorcontrib>Martin, Monique</creatorcontrib><creatorcontrib>Yaltirik, Pelin</creatorcontrib><creatorcontrib>Godeberge, Philippe</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Advances in therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lohsiriwat, Varut</au><au>Sheikh, Parvez</au><au>Bandolon, Robert</au><au>Ren, Dong-Lin</au><au>Roslani, April Camilla</au><au>Schaible, Kassandra</au><au>Freitag, Andreas</au><au>Martin, Monique</au><au>Yaltirik, Pelin</au><au>Godeberge, Philippe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review</atitle><jtitle>Advances in therapy</jtitle><stitle>Adv Ther</stitle><addtitle>Adv Ther</addtitle><date>2023-01-01</date><risdate>2023</risdate><volume>40</volume><issue>1</issue><spage>117</spage><epage>132</epage><pages>117-132</pages><issn>0741-238X</issn><eissn>1865-8652</eissn><abstract>Introduction
Hemorrhoidal disease (HD) is characterized by prolapse of the inflamed and bleeding vascular tissues of the anal canal. Although HD is associated with a high recurrence rate, there is a lack of understanding around interventions that can reduce recurrence and improve outcomes for patients. As such, a systematic literature review (SLR) was conducted to summarize evidence on epidemiology, recurrence, and efficacy of interventions in HD.
Methods
Real-world evidence (RWE) studies evaluating the incidence, prevalence, or recurrence of HD, as well as SLRs including a meta-analytic component reporting on the efficacy of systemic or topical pharmacological treatments for adults with HD, were included. Systematic searches were conducted in MEDLINE, Embase, Cumulative Index to Nursing and Allied Health Literature, and the Cochrane Database of Systematic Reviews.
Results
The SLR identified 44 eligible publications. Consistent data were limited on the epidemiology of HD or HD recurrence. Specifically, incidence and prevalence reported across geographies were impacted by differences in data collection. Reported risk factors for HD were sedentary behavior, constipation, male gender, and age. Twenty-three RWE studies and one meta-analysis reported HD recurrence rates ranging from 0 to 56.5% following surgery or phlebotonics, with most (
n
= 19) reporting rates of 20% or less. In addition to time since treatment, risk factors for recurring disease were similar to those for HD in general. With respect to treatment, micronized purified flavonoid fractions significantly improved the main symptoms of HD compared to other pharmacological treatments.
Conclusion
The SLRs did not identify any RWE studies reporting recurrence in patients receiving systemic or topical treatments, highlighting the need for future research in this area. Further, more studies are needed to understand the optimum duration of medical treatment to prevent recurrence.
Graphical abstract
Plain Language Summary
Patients with hemorrhoidal disease (HD) can experience recurring disease following a period of improvement or remission. It is not well established how often this might happen, who is at greatest risk, or which treatments can reduce this risk. In this study, a systematic literature review (SLR) was conducted to summarize evidence on the occurrence and recurrence of HD, as well as treatment effectiveness. Several literature databases were searched for articles that described real-world evidence (RWE) studies reporting the epidemiology or recurrence of HD as well as published SLRs that combined the results of multiple studies (meta-analyses) on treatment for adults with HD. Forty of 2037 articles identified by the search were considered relevant, and four others identified by clinicians were also included (total = 44; 39 RWE, 5 meta-analyses). Review of the RWE articles revealed that HD epidemiology was determined differently between studies. Only 23 reported recurrence rates (up to 56.5%) after surgery or treatment with phlebotonic drugs (drugs that improve blood flow in veins). Most (19/23) reported recurrence rates of 20% or less. Risk factors for recurrence were similar to usual HD risk factors (e.g., constipation, male gender, age) in addition to time since treatment. Phlebotonic agents, including those made from plant extracts (micronized purified flavonoid fractions, MPFFs) improved hemorrhoidal symptoms compared with placebo or no treatment. In one meta-analysis, MPFF was the only phlebotonic to significantly reduce recurrence risk versus no treatment or placebo. Overall, more research is needed to compare treatments and determine optimal treatment duration to prevent recurrence.
BeGGY4JXaFY15gccdi8jpH
Author-narrated video abstract</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>36331754</pmid><doi>10.1007/s12325-022-02351-7</doi><tpages>16</tpages><orcidid>https://orcid.org/0000-0001-5599-8654</orcidid><orcidid>https://orcid.org/0000-0002-2252-9509</orcidid><orcidid>https://orcid.org/0000-0003-2153-2930</orcidid><orcidid>https://orcid.org/0000-0003-2458-965X</orcidid><orcidid>https://orcid.org/0000-0003-4645-9864</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0741-238X |
ispartof | Advances in therapy, 2023-01, Vol.40 (1), p.117-132 |
issn | 0741-238X 1865-8652 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9859842 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Adult Cardiology Endocrinology Flavonoids Hemorrhage Hemorrhoids - drug therapy Hemorrhoids - epidemiology Humans Internal Medicine Male Medicine Medicine & Public Health Meta-Analysis as Topic Oncology Pharmacology/Toxicology Review Rheumatology Risk Factors |
title | Recurrence Rates and Pharmacological Treatment for Hemorrhoidal Disease: A Systematic Review |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A18%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recurrence%20Rates%20and%20Pharmacological%20Treatment%20for%20Hemorrhoidal%20Disease:%20A%20Systematic%20Review&rft.jtitle=Advances%20in%20therapy&rft.au=Lohsiriwat,%20Varut&rft.date=2023-01-01&rft.volume=40&rft.issue=1&rft.spage=117&rft.epage=132&rft.pages=117-132&rft.issn=0741-238X&rft.eissn=1865-8652&rft_id=info:doi/10.1007/s12325-022-02351-7&rft_dat=%3Cproquest_pubme%3E2732540359%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2732540359&rft_id=info:pmid/36331754&rfr_iscdi=true |